KPV

• Week 1-2: Some users report less bloating within 3 to 7 days
• Week 2-4: Some report calmer gut, skin, or joints; results vary
• Week 4-8: Same dose through the end of week 8
• Week 9-10: 2-week break; see a doctor if gut problems persist
• Side effects: No human safety data; stop for allergic signs or worse gut pain

More on each stage

Week 1-2

Some community users report less bloating, cramping, or bowel irregularity within 3 to 7 days.

Week 2-4

A community page says full benefits are generally reported after 2 to 4 weeks of consistent use: calmer gut days, calmer inflamed skin, less joint stiffness. It also says individual responses vary significantly with the underlying condition and how severe it is.

Week 4-8

Keep the same dose through the end of week 8. Community cycles run 4 to 8 weeks, or longer for long-lasting problems.

Week 9-10

You are on the 2-week break until the end of week 10. Notice whether symptoms come back. If gut problems continue or get worse, see a doctor: ongoing gut inflammation needs a proper diagnosis, and KPV is not a treatment for diagnosed bowel disease. After the break, you can start a new 8-week course.

Side effects

No human safety data. Expect possible redness at the shot site or a mildly upset stomach. Stop and get help for face or throat swelling, trouble breathing, or a hot, spreading red patch.

Based on what people report in the community sources below. Results vary, and many responses are anecdotal.

• Calmer gut inflammation

  Animal/lab study

  In mice with colitis (gut inflammation) triggered by either of two chemicals (DSS or TNBS), KPV added to their drinking water reduced the colitis, seen as a drop in inflammatory signals. A second team, testing DSS colitis and an immune-cell transfer colitis model, found KPV-treated mice recovered sooner, regained more weight, and had less colon inflammation, confirmed by lower activity of MPO (a marker of inflammatory white cells) in colon tissue.12

• Fewer colon tumours in inflamed mice

  Animal/lab study

  In mice given a cancer-causing chemical plus repeated bouts of gut inflammation, KPV in their drinking water sharply reduced colon tumours. It did not protect mice lacking the gut transporter (PepT1) that carries KPV into cells.3

• Calmer irritated skin

  Animal/lab study

  KPV reduced ear-skin swelling from a chemical irritant in mice, with bigger doses working better. In lab-grown human skin cells, it cut inflammation and cell death caused by fine dust.56

• Germ-fighting activity

  Animal/lab study

  In lab dishes, KPV and its parent hormone slowed the growth of Staphylococcus aureus (a common skin bacterium) and weakened Candida albicans (a yeast).8

• No tanning effect

  Animal/lab study

  KPV is the last 3 building blocks of alpha-MSH, the hormone that drives tanning. It keeps the parent hormone's calming effect but lacks its skin-darkening effect, so it does not tan you.91

• Less bloating, calmer skin, less stiffness

  Community report

  Community users report fewer bloating and cramping days, calmer inflamed skin, and less joint stiffness.18

What it has been studied for

• Inflammatory bowel disease (colitis); one study gave KPV by mouth in drinking water12Animal/lab study
• Colon tumours driven by long-term gut inflammation3Animal/lab study
• Colitis treated with KPV packed in tiny particles that release it in the colon4Animal/lab study
• Irritated, inflamed skin56Animal/lab study
• Airway inflammation such as in asthma (human airway cells in a dish)7Animal/lab study

KPV is a tiny piece of a hormone your body already makes, only 3 building blocks (amino acids) long. Inflammation is your body's alarm system: it helps when you are hurt, but sometimes it stays switched on and causes swelling, pain, or an upset gut. Inside each cell is a main switch that turns that alarm on. In mouse and lab studies, KPV slips into cells through a special doorway and turns the switch down, so the cells send out fewer alarm signals. An inflamed gut has more of these doorways, which may be why KPV seems to work best there. Nobody has tested how it works in people yet.

Peak 3 minHalf-life 30 minCleared ~2.5 hrs

Peak

About 3 minutes after the shot, in the estimate charted above. No study has measured KPV levels in people by any route, so treat every number here as an estimate.

Half-life

About 30 minutes (estimate). That fits community references, which expect it to be short because enzymes in the blood quickly break down small peptides like this.

Cleared

About 2.5 hours (estimate), so each dose is gone long before the next one 12 hours later. The FDA says it has found no human exposure data for KPV by any route.

Half-life is how long it takes the body to remove half of a dose.211912

Twice a day. Morning and evening, about 12 hours apart. No study shows a best time of day. Every day. Units are for a 10 mg vial mixed with 1 mL water (10 mg per mL).

• Most common · standard anti-inflammatory dose

  200-500 mcg once daily

  The standard community anti-inflammatory subcutaneous dose for gut-barrier and reactive-skin goals, usually started at the low end and run for 4-8 week cycles.18

Research protocols

• Human studies

  None. The FDA says it has found no human exposure data for KPV by any route, so no human dose has been tested.12

• Mouse colitis study (DSS and TNBS, two chemicals used to trigger colitis)

  KPV added to the drinking water, so the mice took it by mouth. The study summary does not state the amount.1

• Mouse colitis-linked cancer study

  KPV dissolved in the drinking water at 100 micromolar (100 μmol/L, a lab unit of strength), given along with DSS during each of two 7-day DSS cycles.3

• Mouse colitis, KPV in tiny particles

  KPV loaded into nanoparticles inside a gel designed to release it in the colon. It worked about as well as plain KPV at a concentration 12,000 times lower.4

• Mouse skin irritation study

  Graded doses of KPV compared with salt water and a large steroid dose against chemical-irritant ear swelling; swelling fell as the dose rose.5

• Biohacking community (Peptide Protocol Wiki, 40 reports; not a study)

  Most popular: 200 to 500 mcg under the skin once a day for 4 to 8 weeks, starting at the low end. For gut goals, some take 500 to 1,000 mcg by mouth twice a day on an empty stomach. A niche group injects 10 to 20 mg a day for 2 to 4 weeks, 20 to 40 times the usual 500 mcg dose, with no safety data.1819

KPV has no human clinical trial data. The wide community dose range signals how little is established. It acts independently of melanocortin receptors, so tanning or appetite effects some expect from its parent alpha-MSH do not apply.

Dosing guidance built from the cited research and community reports. It is not a prescription.

1. 1
2. 2
3. 3
4. 4
5. 5
6. 6
7. 7
8. 8
9. 9
10. 10

On: 8 weeks Break: 2 weeks

A full course at the store pace takes 6 vials. A mixed vial keeps for up to 90 days.

Why the break helps

The 2-week break shows you whether your gut or skin stays calm without KPV, and it limits nonstop use of a compound whose long-term safety in people is unknown. Community guides say courses can be repeated.

Common

• Redness, pain, or swelling where you injected

  What to do Rotate sites and use a fresh syringe every time. It usually fades on its own. If redness spreads or gets hot and painful, treat it as an infection (see below).

• Mildly upset stomach. A community reference lists it at 1 to 10%, but says this is a general expectation for peptides taken by mouth, not a problem documented with KPV itself, and that no adverse-event data exist.

  What to do Drink water and eat normally. If it keeps happening, drop to 2 units (200 mcg) once a day or stop.

Stop and get help

• Allergic reaction: hives or rash, swelling of the face, lips, or throat, trouble breathing, or feeling faint. Emergency doctors list allergic reactions among the most likely problems with injected research peptides.

  What to do Stop and call 911 (or your local emergency number) right away. Report it to Poison Control at 1-800-222-1222.

• Infection at the injection site: redness that spreads, heat, pus, red streaks, or fever

  What to do Stop injecting and see a doctor the same day. Emergency doctors note the risk is higher with products not approved for human use.

• Gut symptoms that get worse: blood in your stool, black stool, severe belly pain, fever, or weight loss you cannot explain

  What to do Stop KPV and see a doctor promptly. These can be signs of bowel disease that needs real medical treatment.

Do not use if

• You are pregnant, trying to get pregnant, or breastfeeding: there is no safety data.
• You are under 18.
• Your immune system is weakened (for example by medicine after a transplant) or you have an active infection: in theory, damping inflammation could blunt your body's response to germs.
• You compete in a drug-tested sport: WADA bans any drug not approved for human use at all times, and KPV is not approved.

Sources1220

Storage

Keep it

Keep the mixed vial in the fridge (2-8 °C / 36-46 °F), away from heat and light, and never in a hot car. Do not use it if it turns cloudy or changes colour.

How long

Use within 90 days of mixing. A mixed vial kept in the fridge holds its strength for 60-90 days, then slowly starts to lose potency. Wipe the rubber top with an alcohol swab before every draw.

Drawing your dose

Syringe: a 0.5 mL (50-unit) U-100 insulin syringe.

1. With this mix, every 1 unit line on a U-100 insulin syringe holds 100 mcg. Draw to the 5-unit line for 500 mcg, or to 2 units for 200 mcg.
2. The last draw from a vial can come up a little short, because a few drops stay in the vial; tilt the vial and pull from the lowest point.
3. Hold the syringe at eye level, flick out air bubbles, and push the plunger back to the exact line.
4. Pinch a fold of skin on the belly or thigh, insert the needle at 45 to 90 degrees, push slowly, and wait a few seconds before pulling out.
5. Use a new sterile syringe every time and never share one.

• BPC-157

  The most popular community gut stack and part of the store's KLOW stack. KPV calmed colitis in mice, while BPC-157 protected and healed the gut lining in rats.18110

• GHK-Cu

  Part of the store's KLOW stack, aimed at skin. GHK-Cu raises collagen and elastin and supports skin repair, while KPV calmed irritated skin in mice. Lab work suggests both turn down the NF-kB inflammation switch: GHK-Cu in a review of its studies, and KPV in gut cells.1151

Interactions

• Immune-suppressing medicines (steroids such as prednisone, TNF blockers such as adalimumab or infliximab, JAK inhibitors, transplant drugs such as tacrolimus)

  No interaction studies exist in any species. In theory, adding another inflammation-lowering compound could weaken your defence against infection further.

  What to do Ask the doctor who prescribes them before using KPV. Do not stop or change your prescribed medicine.

• Bowel-disease medicines (mesalamine, azathioprine, and similar)

  No interaction studies exist, and the effect of combining them is unknown. KPV has never been tested as a replacement for these medicines.

  What to do Keep taking your prescribed treatment and tell your gastroenterologist you use KPV.

• Other peptides in a stack (BPC-157, GHK-Cu, TB-500)

  Starting several peptides at once makes it hard to tell which one causes a reaction.

  What to do Start one peptide at a time, a week or more apart, so you can tell which one causes a problem.

Videos

• The "Glow Stack": BPC-157, TB-500, GHK-Cu & KPVJoy Kong MD · 2026
• Doctor Reacts to Most Powerful Peptide Stacks (GLOW, KLOW, Wolverine)Dr. Jones, DC · 2025

Sources

1. 1Dalmasso et al., Gastroenterology 2008 (KPV in mouse colitis, PepT1 and NF-kB)Study
2. 2Kannengiesser et al., Inflamm Bowel Dis 2008 (KPV in two mouse colitis models)Study
3. 3Viennois et al., Cell Mol Gastroenterol Hepatol 2016 (KPV and colitis-linked cancer in mice)Study
4. 4Laroui et al., Gastroenterology 2010 (KPV nanoparticles for mouse colitis)Study
5. 5Hiltz & Lipton, FASEB J 1989 (KPV and skin swelling in mice)Study
6. 6Sung et al., Tissue Cell 2025 (KPV in dust-damaged human skin cells)Study
7. 7Land, Int J Physiol Pathophysiol Pharmacol 2012 (KPV in human airway cells)Study
8. 8Cutuli et al., J Leukoc Biol 2000 (antimicrobial effects of alpha-MSH peptides)Study
9. 9Brzoska et al., Endocr Rev 2008 (alpha-MSH and related tripeptides review)Review
10. 10Sikiric et al., Curr Pharm Des 2011 (BPC-157 gastrointestinal review)Review
11. 11Pickart & Margolina, Int J Mol Sci 2018 (GHK-Cu review)Review
12. 12FDA: Bulk drug substances that may present significant safety risks (KPV entry)Reference
13. 13DLA Piper 2026: FDA advisory committee recommends adding six peptides, including KPV, to the compounding bulk listReference
14. 14Buchanan Ingersoll & Rooney (Legalink), Aug 2026: FDA advisory committee voted yes on six peptides, including KPVReference
15. 15CSPI letter to FDA, Oct 2026: the July 2026 committee votes were close, only advisory, and would need rulemakingReference
16. 16German Sport University Cologne: WADA class S0, non-approved substancesReference
17. 17emDocs ToxCard 2026: Peptide toxicity (emergency physicians)Practitioner
18. 18Peptide Protocol Wiki: KPV community protocols (40 reports)Community
19. 19Peptide Protocol Wiki: KPV dosing, mixing, and storageCommunity
20. 20Peptide Protocol Wiki: KPV side effects and interactionsCommunity
21. 21Peptide Protocol Wiki: KPV molecule and pharmacokineticsCommunity

Where people discuss it

• r/Peptides (subreddit)
• Peptide Protocol Wiki — KPV community (40 reports)

Some peptides, like semaglutide (Ozempic and Wegovy), are FDA-approved medicines. Most of the peptides people research are not. That label sounds like the FDA tested something and turned it down. Usually it means something else: nobody has paid for the studies the FDA needs to see. Here is why.

The FDA doesn’t test drugs. Companies do.

The FDA does not run its own drug tests. A company that wants to sell a new medicine has to test it first, and pay for it. It studies the drug in animals, then in people: first 20 to 100 volunteers, then a few hundred, then up to 3,000. Then it sends all the results to the FDA. FDA scientists review them and decide whether the benefits outweigh the risks.

So approval always starts with a company asking for it. If no company applies, the FDA has nothing to review, however promising the research looks.

Those studies cost about a billion dollars

A study in the medical journal JAMA estimated that bringing one new drug to market costs a typical company about $1.1 billion. That figure includes the money spent on drug ideas that failed along the way, because many drugs that start human testing never make it.

A patent is how a company earns that money back

A patent is a right the government gives an inventor. For up to 20 years from the day the inventor applies, nobody else may make or sell the invention without permission.

For a drug company, that right is what makes the billion-dollar bet worth it. While the patent lasts, the company is the only seller, so it can charge enough to pay back the studies and the failures. When the patent runs out, other companies can sell cheap copies, called generics, and the price drops.

The FDA adds a shorter shield of its own. For 5 years after a brand-new drug is approved, no copycat version can apply for approval. That helps, but it is much shorter than a patent can last.

Why most peptides can’t be patented

To get a patent, an invention has to be new, and it has to be something people made, not something found in nature. Most popular peptides fail one test or both.

They come from nature. Many are copies or small pieces of molecules your body already makes. KPV is a 3-building-block piece of the hormone that tans your skin. BPC-157 is copied from a protein in stomach juice. In 2013 the US Supreme Court ruled that something that exists in nature, like a human gene, cannot be patented just because someone found it and pulled it out.

They aren’t new anymore. Many were first described in research papers decades ago. Scientists were already testing KPV in the 1980s. Once something has been published, it no longer counts as new, so nobody can patent it now, and any patents from back then have long since run out.

Without a patent, a company that paid for the studies would soon face rivals selling the same peptide without having paid for any research. Few companies will spend a billion dollars on a product anyone can copy. So nobody goes first, and the large human studies never happen.

The workaround: change the molecule

Drug companies do make peptide medicines, but they change the peptide first. A changed molecule is a new invention, so it can be patented. Semaglutide is a lab-made version of GLP-1, a gut hormone your body releases after meals, changed so one shot lasts a week. Tesamorelin (Egrifta) is the body’s own growth-hormone signal with a small fatty chain added. Both went through the full studies, and both are FDA-approved.

The natural versions, and the many peptides nobody has changed and patented, stay where they are: studied in labs and animals, used by the biohacking community, and never put through large human trials.

What this means for you

When a peptide is “not FDA-approved,” it usually means no company has paid for the large human studies. It does not mean the FDA tested it and found it harmful.

It also does not mean it is proven safe or proven to work. Without those studies, nobody knows the best dose for sure, or what rare or long-term side effects it may have. And the FDA does not check research peptides for purity or strength the way it checks approved medicines. That is why this page labels every finding by the kind of study behind it, and lists who should not use it.

Sources for this section

1. 1FDA: How drugs are developed and approved (the FDA does not test drugs; companies submit the evidence)
2. 2FDA: The drug development process, step 3: clinical research (study sizes for each phase)
3. 3Wouters, McKee & Luyten, JAMA 2020, corrected 2022: median cost to bring a new drug to market, $1.14 billion
4. 4US patent law, 35 U.S.C. § 154: a patent lasts 20 years from the filing date
5. 5FDA: Frequently asked questions on patents and exclusivity (5-year new chemical entity exclusivity)
6. 6US Supreme Court, Association for Molecular Pathology v. Myriad Genetics (2013): naturally occurring genes cannot be patented